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In Brief
Chopin et al. show that the transcription
factor RUNX2 controls the peripheral
homeostasis of plasmacytoid dendritic
cells (pDCs) through the regulation of the
chemokine receptor CXCR4. RUNX2 is
also required for the expression of IRF7
and the production of type I interferon,
the cardinal function of pDCs.
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Plasmacytoid dendritic cells (pDCs) represent a
unique immune cell type that responds to viral nu-
cleic acids through the rapid production of type I
interferons. Within the hematopoietic system, the
transcription factor RUNX2 is exclusively expressed
in pDCs and is required for their peripheral homeo-
stasis. Here, we show that RUNX2 plays an essential
role in promoting pDC localization and function.
RUNX2 is required for the appropriate expression
of the integrin-mediated adhesion machinery, as
well as for the down-modulation of the chemokine re-
ceptor CXCR4, which allows pDC egress into the cir-
culation. RUNX2 also facilitates the robust response
to viral infection through the control of IRF7, the ma-
jor regulator of type I interferon production. Mice
lacking one copy of Runx2 have reduced numbers
of peripheral pDCs and IFN-a expression, which
might contribute to the reported difficulties of indi-
viduals with cleidocranial dysplasia, who are hap-
loinsufficient for RUNX2, to clear viral infections.INTRODUCTION
Dendritic cells (DCs) are professional antigen-presenting cells
(APCs) that have the capacity to prime naive T cells, thereby
initiating the adaptive immune response. To face a variety of
environmental challenges, DCs have evolved into highly sophis-
ticated cellular subsets with distinct functionalities. One major
sub-classification can be made between conventional DCs
(cDCs) and plasmacytoid DCs (pDCs). cDCs are regarded as
the primary APC, whereas pDCs are specialized to sense and
respond to virus derived nucleic acids through the expression
of Toll-like receptor (TLR) 7 and 9, IRF7 (Honda et al., 2005),
and the rapid production of type I interferon (IFN) (Cella et al.,
1999; Ro¨nnblom et al., 1983; Siegal et al., 1999). Activated
pDCs are also capable of recruiting immune cells including866 Cell Reports 15, 866–878, April 26, 2016 ª2016 The Authors
This is an open access article under the CC BY-NC-ND license (http://T cells to the inflammatory sites through their secretion of che-
mokines (Krug et al., 2002; Vanbervliet et al., 2003).
Despite the importance of pDCs for immune responses, our
understanding of themechanisms underpinning pDC differentia-
tion, homeostasis, and trafficking remain limited. The transcrip-
tion factor E2.2, encoded by Tcf4, is essential for the early
differentiation of pDCs in the bone marrow (BM; Cisse et al.,
2008) and maintains the identity of mature pDCs (Ghosh et al.,
2010). RUNX2 represents another important regulator of pDC
differentiation as mice reconstituted with RUNX2-deficient fetal
liver stem cells have a cell-intrinsic defect in pDC maturation
(Sawai et al., 2013). The function of RUNX2, also known as
core-binding factor subunit alpha-1 (CBF-alpha-1), is well char-
acterized in bone-forming cells, the osteoblasts, where it plays
an essential role for their differentiation (Komori et al., 1997;
Otto et al., 1997). In humans, haploinsufficiency inRUNX2 results
in the bone disease cleidocranial dysplasia (CCD). In addition to
suffering skeletal disorders, these individuals endure persistent
ear, sinus, and upper airway infections (Cooper et al., 2001)
that potentially reflect a deficiency in pDC frequency or function.
Here, we have examined the consequences of loss of RUNX2
for the pDC lineage using gene-targeted mice. We find that
RUNX2 regulates the abundance of peripheral pDCs in large
part through its control of the trophic chemokine receptor
CXCR4. Ablation of either a single or both copies of Runx2 re-
sulted in increased CXCR4 expression and impaired BM egress.
RUNX2 also played a critical and gene dosage-dependent role in
pDC function, through the regulation of Irf7 and thus the type I
IFN production, that was associated with a failure to mount an
optimal immune response to acute viral challenge. Thus
RUNX2 is both a regulator of pDC peripheral localization and a
promoter of antiviral immune function.
RESULTS
RUNX2 Is Required for Peripheral pDC Homeostasis
RUNX2 is a well-known transcription factor controlling osteo-
blast differentiation and skeletal morphogenesis, whose defi-
ciency in mice results in perinatal lethality (Komori et al.,
1997; Otto et al., 1997). Runx2 has also been identified increativecommons.org/licenses/by-nc-nd/4.0/).
transcriptome-based screens as being highly and specifically
expressed by pDCs (Crozat et al., 2010; Manh et al., 2013; Miller
et al., 2012; Sawai et al., 2013), a findingwe have corroborated at
the protein level using a newly developed anti-RUNX2 mono-
clonal antibody (Figure S1A).
Fetal liver reconstitution approaches have previously re-
vealed that RUNX2 is required for the emergence of mature
pDCs in peripheral organs, potentially through the regulation
of the chemokine receptors CCR2 and CCR5 (Sawai et al.,
2013). Beyond this observation, there is little understanding
as to how RUNX2 controls pDC homeostasis. To facilitate ad-
dressing this question, we have generated a new mouse strain
in which the second exon of Runx2 was flanked with LoxP sites
(Runx2fl/fl; Figure S1B; Owens et al., 2014). This strain was
then crossed to the Rosa26-CreERT2 allele, resulting in the
generation of CreERT2+Runx2fl/fl mice, hereafter referred as
Runx2 cKO. Administration of tamoxifen by gavage resulted
in efficient recombination between the LoxP sites, deletion of
Runx2 exon 2, and the loss of RUNX2 protein in pDCs (Figures
S1C and S1D).
To circumvent the potential non-cell intrinsic role of osteo-
blasts in the development of the BM compartment, chimeric
mice were generated where congenic C57Bl/6-Ly5.1 mice
were lethally irradiated and reconstituted with CreERT2+
Runx2+/+ (wild-type [WT]) or Runx2 cKO BM cells (both Ly5.2+)
isolated from mice previously treated with tamoxifen. In line
with a previous report (Sawai et al., 2013), RUNX2 deficiency
led to sharply reduced numbers of pDCs in peripheral lymphoid
organs and tissues but did not impede the development of pDCs
in the BM (Figure 1A) or their generation in the presence of Flt3L
in vitro (data not shown).
Despite their normal frequency, the Runx2 cKO BM pDCs dis-
played a disturbed cell-surface phenotype. While previous
studies have noted the reduced expression of the pan-DC
marker CD11c in the absence of RUNX2 (Satpathy et al., 2014;
Sawai et al., 2013), we also observed reduced expression of
the common pDC markers MHCII and SiglecH, while CXCR3
was increased in cKO pDCs (Figure 1B). In contrast, Ly49Q
expression, whose upregulation tracks with pDC maturation
(Kamogawa-Schifter et al., 2005), was equivalent between the
genotypes, suggesting that phenotypically mature pDCs arise
in the absence of RUNX2 (Figure 1C).
RUNX2Regulates Integrin-Mediated Adherence in pDCs
To better understand the failure of Runx2 cKO pDCs to home to
the periphery, we analyzed the expression of several integrin
molecules on the cell surface of pDCs and cDCs. As shown
above, Runx2 cKO pDCs expressed markedly less Integrin aX
(CD11c) compared to their WT counterparts (Figure 1B). Runx2
cKO pDCs also showed impaired expression of Integrin aL
(CD11a), Integrin b2 (CD18), and Integrin a4 (CD49d; Figure 2A).
As expected Runx2 cKO cDCs did not show any change in the
expression of these integrins (Figure 2A). The reduced expres-
sion of these key adhesion molecules in Runx2 cKO pDCs was
also observed in Flt3L-derived pDCs in vitro (Figure 2B). qRT-
PCR analysis of the WT and Runx2 cKO BM pDCs confirmed
that the regulation of Itgax (CD11c) and Itgal (CD11a) was tran-
scriptional. In contrast, no change in the expression of Itgb2(encoding CD18) was observed, suggesting that the reduction
in cell-surface CD18 was an indirect consequence of the
reduced expression of the Integrin aX and Integrin aL chains it
often pairs with (Figure 2C).
To address the functional consequences of the altered integrin
expression by Runx2 cKO pDCs, we performed an in vitro assay
where cells were examined for their capacity to adhere to extra-
cellular cell matrix components such as fibronectin or ICAM-1. In
line with their reduced integrin expression, Runx2 cKO pDCs
were significantly less adherent thanWT pDCs exposed to either
ligand (Figure 2D). Inhibiting integrin function through the addi-
tion of calcium and magnesium chelating agents totally abro-
gated the adhesion properties of both WT and Runx2 cKO
pDCs. These observations highlight the central role played by
RUNX2 in controlling the expression of cell adhesion compo-
nents, key molecules in enabling the cells to trans-migrate
across the vascular endothelium.
CXCR4 Tethers pDCs to the Bone Marrow
The impaired integrin-mediated adhesion properties of Runx2
cKO pDCs might result in improper localization in the BM and
ultimately render these cells refractive to egress signals. In
contrast to cDCs that respond to a wide variety of chemokine li-
gands, human and murine pDCs show poor migratory behavior
when exposed to chemoattractants (de la Rosa et al., 2003;
Penna et al., 2002). While their motility can be increased signifi-
cantly with the addition of a supporting layer of endothelial cells,
the only chemokine shown to induce significant pDC transmigra-
tion is CXCL12, the ligand for CXCR4 (de la Rosa et al., 2003;
Kohara et al., 2007; Penna et al., 2002). Interestingly, positioning
of B cells within the BM has been correlated with the levels of
CXCR4 expression, and the desensitization of the cells to
CXCL12, through the downregulation the CXCR4, was key to
promote B cell egress (Beck et al., 2014; Pereira et al., 2009).
This led us to explore the possibility that the normal maturation
program of pDCs within the BM, as assessed by the marker
Ly49Q, was associated with reduced expression of CXCR4.
Concordant with this hypothesis, we found that Ly49Q– pDCs
displayed higher levels of CXCR4 than Ly49Q+ pDCs (Figure 3A).
To functionally assess the relevance of these findings, WT pDCs
isolated from the BM were subjected to a transwell assay where
the responsiveness of pDCs to CXCL12 was monitored by flow
cytometry. pDCs were highly sensitive to CXCL12-induced
chemotaxis, and phenotypic characterization of the migrated
pDCs revealed that Ly49Q– pDCs were more sensitive than their
Ly49Q+ counterparts (Figure 3B).
Given their responsiveness to CXCL12, we hypothesized that
Ly49Q– immature pDCs and Ly49Q+ mature pDCs might reside
in distinct BM compartments, with the Ly49Q+ fraction being
closer to the circulation. To test this hypothesis, we adapted
an in vivo labeling procedure that discriminates localization in
the sinusoids from the parenchyma, the latter being the less
likely to be labeled shortly after injection of a monoclonal anti-
body (mAb) (Pereira et al., 2009). WT mice were injected intrave-
nously (i.v.) with labeled CD45.2 mAb, and the proportions of
bound Ly49Q– and Ly49Q+ pDCs were compared 2 min later.
We observed that CD45.2-labeled Ly49Q+ pDCs were twice as
frequent as Ly49Q– pDCs (Figure 3C), suggesting that the formerCell Reports 15, 866–878, April 26, 2016 867
Figure 1. Loss of Runx2 Impairs pDC Localization to the Periphery
(A) Flow cytometry analyzing the expression of Bst2 and B220 within Ly5.2+ cells 6 weeks after reconstitution of lethally irradiated C57Bl/6-Ly5.1+ mice with WT
Ly5.2+ or cKO Ly5.2+ BM. Numbers indicate the percentage of cells in each box. Bar graphs show themean proportion ±SD (n = 5 per genotype) of pDCs found in
the indicated organs.
(B) Histograms depicting the expression of CD11c, MHCII, CXCR3, SiglecH, and CCR9 in pDCs (gated as in A) isolated fromWT (red line) and cKO BM (blue line).
Bar graphs show the mean fluorescence intensity (MFI) ±SD for the indicated cell-surface markers on WT and cKO pDCs (n = 5 per genotype).
(C) Histograms depicting the expression of Ly49Q on WT and cKO pDCs (gated as in A) isolated from the BM and spleen. Data presented in this figure are from
one experiment and are representative of three independent experiments.
*p < 0.05, **p < 0.01, ***p < 0.001 (unpaired Student’s t test) compared to WT sample. ns, not significant p > 0.05. See also Figure S1.reside in close proximity to the sinusoids, while immature Ly49Q–
pDCs are found deeper in the parenchyma.
As RUNX2-deficient pDCs showed impaired adhesion proper-
ties, it was conceivable that these cells would be improperly
localized, rendering them refractive to egress signals. Therefore,
we examined WT and Runx2 cKO mice after i.v. injection with a
mAb directed against B220, as described above. Approximately
75% of the WT and Runx2 cKO pDCs were labeled by this pro-
cedure, suggesting that cells of both genotypes reside in similar
niches within the BM (Figure 4A). However, a phenotypic com-
parison of the pDCs revealed that unlabeled Runx2 cKO pDCs
expressed a higher level of CXCR4 compared to their WT coun-
terparts (Figure 4A). Analysis of WT and Runx2 cKO pDCs iso-
lated from the BM confirmed that CXCR4 protein, and mRNA868 Cell Reports 15, 866–878, April 26, 2016was specifically upregulated in Runx2 cKO pDCs (Figures 4B
and 4C). This aberrant expression resulted in a greater respon-
siveness to a CXCL12 gradient by Runx2 cKO pDCs when
compared to WT (Figure 4D). Thus, despite residing in similar
compartments to WT, Runx2 cKO pDCs express more CXCR4,
and this may impair the release of cKO pDCs into the periphery.
To test the importance of desensitization of the CXCL12/
CXCR4 axis in mobilizing pDCs from the BM into the circulation,
WT and Runx2 cKOmice were treated with 100 mg of the CXCR4
antagonist AMD3100, shown to rapidly induce the mobilization
of stem cells to the peripheral blood (Broxmeyer et al., 2005;
Liles et al., 2003). WT mice treated with AMD3100 showed
greatly increased numbers of circulating pDCs in the blood,
including the immature Ly49Q–, fraction, consistent with the
Figure 2. Loss of Runx2 Impairs pDC Adhesion Properties
(A) Flow cytometric analysis of the expression of CD11a, CD49d, and CD18 on
Ly5.2+ BM pDCs (Bst2+ B220+) and splenic cDCs (CD11c+ MHCII+) isolated
from lethally irradiated congenic C57Bl/6-Ly5.1+ mice reconstituted with WT
Ly5.2+ or cKO Ly5.2+ BM. Bar graphs show the mean fluorescence intensity
(MFI) ±SD (WT, red bar; cKO, blue bar).
(B) Flow cytometry analyzing the expression of CD11c, CD18, CD49d, and
CD11a on in vitro Flt3L generated pDCs (Bst2+ B220+) from WT or cKO BM.
(C) qRT-PCR for expression of Itgax, Itgal, and Itgb2 in WT and cKO BM pDCs.
Data are the mean ± SD and are normalized to Hprt.
(D) Bar graphs show the mean percentage of adherent BM pDCs ±SD to
ICAM-1 and fibronectin. Data in this figure are from one experiment (n = 5 per
genotype for A and B; n = 3 per genotype for D) and are representative of two
independent experiments.
*p < 0.05, **p < 0.01, ***p < 0.001 (unpaired Student’s t test) compared to WT
sample.
Figure 3. CXCR4 Is Downregulated during pDC Maturation
(A) Flow cytometry analyzing the expression of CXCR4 and Ly49Q (right dot
plot) on pDCs (left contour plot) isolated from the BM of a C57Bl/6 mouse. Bar
graphs show the mean fluorescence intensity (MFI) ±SD of CXCR4 on Ly49Q–
(gray bar) and Ly49Q+ pDCs (black bar). Data are from one experiment (n = 4
per genotype) and are representative of two independent experiments.
(B) Line chart represents the mean ± SD chemotactic response of Ly49Q–
(gray line) and Ly49Q+ pDCs (black line) to an increasing concentration of
CXCL12. Data are from one experiment (n = 3 per genotype) and are repre-
sentative of two independent experiments.
(C) Flow cytometry analyzing the extent of labeling of C57Bl/6 pDCs (CD11c+
SiglecH+, top left) according to their ly49Q expression (top right) 2 min after the
i.v. administration of anti-CD45.2-PE (n = 3 per genotype). Numbers indicate
the frequency of cells within each gate. Histogram (bottom left) shows a
representative staining for CD45.2 on gated Ly49Q– and Ly49Q+ pDCs
(CD11c+ SiglecH+). Bar graph shows the mean proportion of labeled cells ±SD
according to Ly49Q expression. Data are from one experiment (n = 3 per
genotype) and are representative of three independent experiments.
*p < 0.05, **p < 0.01, ***p < 0.001 (unpaired Student’s t test).
Cell Reports 15, 866–878, April 26, 2016 869
Figure 4. Runx2 Controls CXCR4 Expression in pDCs
(A) Flow cytometry analyzing the extent of labeling of WT and cKO pDCs (CD11c+ Bst2+, left plots) 2 min after the i.v. administration of anti-B220-PE (n = 3 per
genotype). Numbers indicate the frequency of cells within each gate. Bar graph shows theMFI ±SD of CXCR4 in unlabeled (B220low) and labeled (B220high) pDCs.
Data are from one experiment (n = 3 per genotype) and are representative of three independent experiments.
(B) Flow cytometry analyzing the expression of CXCR4 on Ly49Q– (top) and Ly49Q+ (bottom) pDCs (Bst2+B220+) isolated from WT (red line) and cKO (blue line)
BM. Bar graphs depict the MFI of CXCR4 ±SD (n = 4).
(C) qRT-PCR for expression of Cxcr4 in WT and cKO BM pDCs. Data are the mean ± SD and are normalized to the Hprt.
(D) Chart represents the mean ± SD chemotactic response of WT (red line) or cKO (blue line) Ly49Q– (left) and Ly49Q+ (right) pDCs to an increasing concentration
of CXCL12 (n = 3).
(E) Flow cytometry analyzing the expression of Bst2 and Ly49Q in blood circulating pDCs (Bst2+B220+) in mice treated with either a saline solution or AMD3100.
Numbers represent the frequency of each subset. Bar graph represents the mean number ±SD of circulating pDCs in the blood of WT and cKOmice treated with
either a saline solution (black bar) or AMD3100 (gray bar, n = 3 mice per genotype). Data presented in (D) and (E) are from one experiment and representative of
two independent experiments.
(F) Flow cytometry analyzing the expression of CXCR4 on CD11c+ cells transduced (GFP+) with either empty control vector (black line) or Runx2 encoding vector
(gray filled histogram, n = 3 per genotype). Bar graphs represent the MFI ±SD of CXCR4 in untransduced (GFP–) and transduced (GFP+) CD11c+ cells.
Data shown are from one experiment (n = 3 per genotype/viral construct) and are representative of three independent experiments. *p < 0.05, **p < 0.01 (unpaired
Student’s t test). ns, not significant p > 0.05.concept that CXCR4 expression on these cells promotes their
retention in the BM (Figure 4E). Strikingly, treatment of the
Runx2 cKO mice with AMD3100 completely restored circulating
pDC numbers, demonstrating that the increased CXCR4 without
RUNX2 blocks BM pDC egress (Figure 4E).870 Cell Reports 15, 866–878, April 26, 2016To examine the possibility that RUNX2 directly affects the
expression of CXCR4, we transduced WT Flt3L-derived DCs
with retroviral vectors expressing either GFP alone or RUNX2
and GFP from a bicistronic transcript. Strikingly, RUNX2 overex-
pression significantly reduced the expression of CXCR4 by
Figure 5. Runx2 Haploinsufficiency Im-
paired Peripheral Localization of pDCs
(A) Flow cytometry of RUNX2 expression in BM
B cells (gray filled histograms) and pDCs (black
line histograms) of the indicated genotype. hz,
Runx2fl/+Rosa26CreERT2+ heterozygous mice.
Numbers indicate mean fluorescence intensity
(MFI) for the respective population. Data pre-
sented are from one experiment and representa-
tive of two independent experiments
(B) Flow cytometry analyzing the presence of
pDCs (Bst2+ B220+) in the spleen, liver, and lung
for the indicated genotype (n = 6 mice per geno-
type). Numbers indicate the frequency of gated
pDCs. Bar graphs represent the mean absolute
numbers of pDCs ±SD for the indicated genotype
in the spleen, lung, and liver.
(C) Bar graphs show the MFI ±SD of the indicated
markers on the surface of pDCs, gated as in (B),
isolated form BM of the indicated genotype (n = 4
mice per genotype).
*p < 0.05, **p < 0.01, ***p < 0.001 (unpaired Stu-
dent’s t test) compared to WT sample. ns, not
significant p > 0.05.CD11c+ cells compared to DCs transduced GFP alone (Fig-
ure 4F). Taken together, these results suggest that RUNX2 is
an essential repressor of CXCR4 expression, and that the normal
desensitization of maturing pDCs to the chemokine CXCL12 is a
key regulatory mechanism to release pDCs from their BM niche.
Runx2Haploinsufficiency Leads to aDecreased Number
of Peripheral pDCs
In humans, haploinsufficiency for RUNX2 leads to a hereditary
skeletal disorder, CCD (Mundlos et al., 1997). A worldwide re-
view of 90 CCD individuals revealed that they commonly sufferCesinus/ear infections and upper airway
complications, conditions that have
been at present associated with their
skeletal deformations (Cooper et al.,
2001). An alternative explanation for
these recurrent infections would be the
inability of the immune system to control
viral infections. To test this hypothesis,
we treated CreERT2+ Runx2+fl mice with
tamoxifen by oral gavage (hereafter
termed Runx2 hz). Three weeks post-
treatment, BM cells were harvested and
the expression of RUNX2 was measured
by flow cytometry. We observed that
RUNX2 concentration was halved with
the inactivation of one Runx2 allele (Fig-
ure 5A). As expected, BM development
was normal; however, the numbers of
pDCs in the peripheral organs such as
the spleen, mesenteric lymph node, and
liver were reduced significantly in Runx2
hz mice and were further reduced in
Runx2 cKO mice (Figure 5B). Heterozy-gosity for Runx2 also led to reduced expression of CD11c, and
increased expression of CXCR3 and CXCR4 (Figure 5C). These
observations confirm that haploinsufficiency of Runx2 impacts
the homeostasis of mouse pDCs.
pDCs Control T Cell Response to Lymphocytic
Choriomeningititis Virus
Given the unique characteristic of pDCs as early type I IFN pro-
ducers upon infection, it has been concluded that their loss is
detrimental for viral clearance (Cervantes-Barragan et al.,
2007, 2012; Jung et al., 2008). However, this remains a matterll Reports 15, 866–878, April 26, 2016 871
of debate, as depletion of pDCs by mAb treatment resulted in
normal serum levels of type I IFNs and unperturbed viral clear-
ance (Hervas-Stubbs et al., 2014). To date, the Runx2 cKO is
the only mouse model where pDCs are formed in the BM but
are substantially reduced in the periphery, thus representing a
unique tool to address the function of peripheral pDCs upon virus
infection.
We reconstituted lethally irradiated congenic C57Bl/6-Ly5.1+
recipients with either WT or Runx2 cKO BM (both Ly5.2+).
These mice were then infected with 103 plaque-forming units
(PFUs) of lymphocytic choriomeningititis virus (LCMV) WE.
Mice reconstituted with WT BM mounted a robust response,
as measured by the serum levels of IFN-a 24 hr post-infection.
Strikingly no IFN-a was detected in sera from infected mice re-
constituted with Runx2 cKO BM. By 96 hr post-infection, serum
IFN-a concentrations were equivalent between the genotypes,
possibly reflecting the contribution from other cell types (Fig-
ure 6A). Analysis of the T cell response 8 days post-infection
revealed a significant reduction in the frequency of LCMV-spe-
cific CD8+ T cells in recipients reconstituted with Runx2 cKO
BM (Figure 6B). In line with this finding, IFN-g production by
CD8+ T cells was reduced in Runx2 cKO chimeras when cells
were restimulated in vitro with LCMV gp33 peptide (Figure 6C).
Interestingly, expression of the inhibitory molecule PD1 was
increased on LCMV-specific CD8+ T cells in recipients of
Runx2 cKO BM when compared to the expression found on
WT LCMV-specific CD8+ T cells (Figure 6D). Finally, splenic
LCMV titers were higher in Runx2 cKO mice compared to WT
controls (Figure 6E). Together these data suggest that RUNX2
function in pDCs is important to promote an optimal antiviral
CD8+ T cell response.
In the above experiment, an intrinsic role for RUNX2 in CD8+
T cells could not be excluded as it has recently been postulated
that RUNX2 plays a role in effector/memory CD8+ T cell develop-
ment and function (Arsenio et al., 2014; Hu and Chen, 2013). In
line with these reports, we observed a slight, nevertheless repro-
ducible, increase inRunx2mRNA in the KLRG1+ fraction of CD8+
T cells that have been exposed to LCMV (Figure S2). To rule out
this explanation for the impaired CD8+ T cell response, and at the
same time addressing the consequences of the reduced number
of pDCs in the periphery, we established mix chimeras, where
C57Bl6-Ly5.2/Ly5.1 F1 mice were lethally irradiated and recon-
stituted with either a mix of 50%WT Ly5.1+: 50%WT Ly5.2+ BM
(WT:WT) or a mix of 50%WT Ly5.1+: 50%Runx2 cKO Ly5.2+ BM
(WT:cKO) (Figure 6F). After reconstitution, mice were infected
with LCMV WE. Strikingly, serum IFN-a levels were dramatically
reduced in WT:cKO mice 24 hr post-infection (Figure 6G). Char-
acterization of the T cell response 8 days post infection revealed
that CD8+ T cells in the shared host behaved similarly with re-
gards to the production of LCMV-specific CD8+ T cells and ex-
pressed equivalent levels of PD1 (Figure 6H). That is, PD1
expression was substantially higher in CD8+ T cells isolated
from recipients mice that received the WT:cKO BM mix,
compared to the cells responding to LCMV in the WT:WT chi-
meras (Figure 6H). This high PD1 expression was associated
with a higher viral load in WT:cKO chimeras (Figure 6I). Taken
together, these observations show that while RUNX2 does not
play an essential cell intrinsic role in LCMV-specific CD8+872 Cell Reports 15, 866–878, April 26, 2016T cells, the potency of the response is related to the amplitude
of type I IFN produced by pDCs at the onset of infection.
RUNX2 Controls Irf7 Expression
The absence of serum IFN-a in Runx2 cKO mice very early after
infection with LCMV, despite the normal frequency of BM pDCs
and residual pDC in the periphery led us to hypothesize that
RUNX2 cKO pDCs were dysfunctional. Indeed, a previous study
found that mice reconstituted with Runx2-deficient fetal liver
produced little IFN-a after injection with CpG (Sawai et al.,
2013). To investigate this possibility, pDCs from WT and Runx2
cKO BM were harvested and either left to rest or stimulated in
the presence of the TLR9 ligand CpG for 3 hr, and the expression
of key components of this pathway, Irf7, Ifna, and Ifnb, was as-
sessed by qRT-PCR. Strikingly, the expression of Irf7 was
reduced in both resting and CpG-activated pDCs in the absence
of RUNX2, resulting in a greatly reduced production of Ifna and
Ifnb (Figure 7A). Runx2 hz pDCs also showed a partial reduction
in both Irf7 and Ifna transcripts after CpG stimulation, while Tlr9
expression was independent of RUNX2 (Figure S3). The reduced
expression of IFN-a protein in CpG-stimulated Runx2 cKO pDCs
was confirmed by intracellular flow cytometry (Figure 7B) and
ELISA (Figure 7C).
To investigate how RUNX2 controls Irf7 expression, we trans-
duced WT Flt3L-derived DCs with retroviral vectors expressing
either GFP alone or RUNX2 and GFP as described above.
RUNX2 overexpression significantly increased the expression
of Irf7 in pDCs compared to GFP-expressing controls (Fig-
ure 7D), suggesting that RUNX2 might directly regulate Irf7
expression. RUNX proteins have been found to co-associate
with the transcription factor PU.1 at gene regulatory regions
(Gu et al., 2014; Petrovick et al., 1998). In silico analysis of the
Irf7 locus revealed one evolutionary conserved region contain-
ing a predicted core-binding factor (CBF) site, in a very close
proximity to the binding of PU.1 (Figure 7E). RUNX2 chromatin
immunoprecipitation (ChIP) in the RUNX2-expressing MC3T3
cell line (Meyer et al., 2014) confirmed its occupancy in this
particular region of Irf7 locus, at least in an osteoblast-like cell
line (Figure 7F). Future development of a ChIP sequencing
(ChIP-seq) assay is now required to confirm the exact mode
of action of RUNX2 in regulating Irf7 in pDCs. Taken together,
these data demonstrate that RUNX2 activity is pivotal to pro-
mote Irf7 expression and thus the type I IFN response, in a
dose-dependent manner.
DISCUSSION
Despite their critical role in sensing nucleic acids from viruses,
the mechanisms regulating pDC homeostasis and function
remain ill defined. Here, we have identified the RUNX2-depen-
dent repression of Cxcr4 as the critical mechanism controlling
pDC egress from the BM and peripheral homeostasis. RUNX2
was also essential for an optimal type I IFN response through
the regulation of Irf7. RUNX2 controlled peripheral pDC fre-
quency and antiviral function in a dose-dependent manner, sug-
gesting that the absolute number of pDCs and the magnitude of
the initial type I IFN response is a critical determinant of an
optimal response.
Figure 6. Reduced Numbers of Peripheral pDC Numbers Is Detrimental to the CD8+ T Cell Response
(A–E) Lethally irradiated C57Bl/6-Ly5.1+ mice were reconstituted with either WT or cKO BM (both Ly5.2+) and infected with LCMV 6 weeks later. (A) Bar graph
represents serum IFN-a concentration in WT and cKO reconstituted mice 24 and 96 hr post-LCMV infection. Bars indicate mean ± SD, and circles depict in-
dividual mice (n = 6). (B) Flow cytometry analyzing the LCMV-specific gp33+ or np396+ splenic CD8+ T cell response at day 8 post-infection (boxed). Bar graph
shows the mean ± SD proportion of gp33+ or np396+ among the CD8+ T cells (n = 6). (C) Flow cytometry analyzing Granzyme B and IFN-g expression by CD8+
T cells 4 hr post in vitro restimulation with gp33 peptide. Numbers indicate the frequency of cells contained in each quadrant. (D) Flow cytometry analyzing PD1
expression of LCMV-specific (gp33 or np396) CD8+ T cells day 8 post infection. Bar graph depicts the mean fluorescence intensity (MFI) ±SD of PD1 in WT and
cKO LCMV-specific CD8+ T cells (n = 6). (E) Chart shows the splenic viral load at day 8 post LCMV infection (n = 6). Bars indicate mean ± SD, and symbols depict
individual mice analyzed. Dashed line shows the limit of virus detection in this assay. Data in (A)–(E) are from one experiment (n = 6 per genotype) and are
representative of two independent experiments.
(F–I) F1 C57Bl/6-Ly5.1 Mice were reconstituted with a 50%:50%mix of either WT Ly5.1+: WT Ly5.2+ BM or WT Ly5.1+: cKO Ly5.2+ BM and infected with LCMV
6weeks later and analyzed at day 8 post-infection. (F) Flow cytometric analysis of splenic chimerism prior to infection. Numbers indicate the proportion of cells in
each quadrant. (G) Graph shows serum IFN-a concentration of chimeric mice 24 hr post-LCMV infection. Bars indicate mean ± SD, and circle/triangle depict
(legend continued on next page)
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Figure 7. RUNX2 Controls Irf7 Expression
(A) qRT-PCR for the expression of the indicated genes in either resting or CpG-stimulated (3 hr) pDCs isolated from the BM of WT (red) or cKO (blue) (n = 3 per
genotype and treatment).
(B) Representative intracellular staining of IFN-a production in resting or 3-hr-activated Bst2+ B220+ gated cells isolated from WT or cKO BM. Data shown are
from a representative of three independent experiments
(C) Bars indicate mean ± SD of IFN-a production measured by ELISA of sorted pDC fromWT (red bar) and cKO (blue bar) stimulated overnight with CpG (n = 4 per
genotype). Data are from a representative of two independent experiments.
(D) qRT-PCR for the expression of Irf7 in pDCs that were either untransduced (GFP–: black bars) or transduced (GFP+: green bars) either with empty vector (GFP
alone) or a vector encoding for RUNX2 (and GFP). Data shown are from one experiment, performed in triplicate, and are representative of two independent
experiments. Data in (A) and (D) are the mean expression (normalized to the Hprt) ±SD.
(E) ChIP-seq tracks for PU.1 binding and input control within the Irf7 locus in Flt3L cultured pDCs. PU.1 peak is shown together with the exon-intron structure of
Irf7 and a scale bar in kilobases (Kb). The data are from a representative of two experiments.
(F) ChIP-seq tracks for RUNX2 binding and input control in the Irf7 locus in MC3T3 cells (Meyer et al., 2014).
Red bar in (E) and (F) indicates a predicted, evolutionary conserved, CBF (RUNX/CBFb complex) binding site in the Irf7 locus that is potentially co-bound by PU.1
and CBF (ECR browser). See also Figure S3.There is to date very limited understanding on the factors,
such as chemokines, that control pDC egress from the BM.
Chemokines can be divided into two categories: homeostatic
and inflammatory (Zlotnik and Yoshie, 2000). The former are
constitutively expressed in a given tissue, suggesting a specific
role in controlling homeostatic cell localization. The inflammatory
chemokines, in contrast, are strongly upregulated by inflamma-
tion or immune stimuli and play key roles in setting up immune
responses. The inflammatory chemokines CCL5 and CCL2, the
ligands for CCR5 and CCR2, respectively, have been suggested
to be the RUNX2-dependent chemokine receptors inducing pDC
egress from the BM (Sawai et al., 2013). However, steady-state
pDCs respond poorly to CCR5/CCR2 ligands, despite express-individual mice analyzed (n = 10 per genotype). (H) Bar graphs depict the mean fl
post-infection. (I) Chart shows the splenic viral load in chimeric mice at day 8 pos
individual mice analyzed. Data presented in (F), (H), and (I) are from one exper
experiments. (G) shows pooled data from the two independent experiments.
*p < 0.05, **p < 0.01, ***p < 0.001 (unpaired Student’s t test). See also Figure S2
874 Cell Reports 15, 866–878, April 26, 2016ing these receptors on their cell surface (de la Rosa et al., 2003;
Penna et al., 2002), while Ccr5/ mice display normal numbers
of steady-state splenic pDCs, with only a very mild defect being
observed in the presence of WT competitor (Sawai et al., 2013).
Therefore, although RUNX2 regulates the expression of CCR2
and CCR5 in pDCs, the impaired activity of these chemokine
receptors is unlikely to account for the diminished number of pe-
ripheral pDCs observed in Runx2 cKO mice and may instead
play a role in pDC localization within peripheral tissues in
response to inflammatory cues.
To facilitate the transport of leukocytes, the BM is traversed
by thin-walled endothelial venules, the sinusoids. Mature cells
are delivered into circulation by passing through this singleuorescent intensity (MFI) ±SD of PD1 on LCMV-specific CD8+ T cells at day 8
t-LCMV infection (n = 5). Bars indicate mean ± SD, and circle/triangle depicts
iment (n = 5 mice per genotype) and are representative of two independent
.
endothelial cell layer through transmigration to enter the circula-
tion. Integrins play an essential role in tethering the cells to sites
of transmigration in response to external cues. RUNX2 was
essential for the normal expression of several integrins, which
we found to be responsible for their firm adhesion to extracellular
matrix components. This finding led us to hypothesize that
Runx2 deficient pDCs might be mislocalized in the BM microen-
vironment. However, in vivo labeling experiments showed that
the ratio of pDCs in close proximity to the sinusoids was similar
inWT andRunx2cKO. Nevertheless, these experiments revealed
that the maturation and positioning of pDCs within the BM was
correlated with the expression of the homeostatic chemokine re-
ceptor CXCR4. Importantly, CXCR4 expression in pDCs was
repressed by RUNX2 in a dose-dependent manner, providing a
clear mechanism for the BM retention of Runx2 cKO pDCs.
Our findings are reminiscent of the recent observations that
CXCR4 expression was necessary for the retention of immature
B cells in the BM, while its downregulation on mature B cells led
to the release of immature cells from the BM (Beck et al., 2014).
Concordantly, we found that blocking CXCR4 with a small mole-
cule antagonist induced strong mobilization of pDCs from the
circulation into the periphery. Given that upon CXCR4 blockade
Runx2 cKO pDCs were released into the blood to the same
extent as WT pDCs, we propose that controlling CXCR4 expres-
sion is the predominant function of RUNX2 regulating the local-
ization of pDCs. This finding also suggests that the role of
integrins in the transmigratory events occurring across the
sinusoidal endothelium from the BM parenchyma to the blood
circulation appears minor. It remains possible that the impaired
adhesion properties observed for Runx2 cKO pDCs impacts
their recruitment into peripheral sites such as lymph nodes, as
the mechanism of entry through high endothelial venules re-
quires firm integrin-mediated adhesion.
Loss of one functional RUNX2 allele in humans leads to de-
fects in bone development and CCD (Otto et al., 1997). Interest-
ingly some CCD patients suffer sinus/ear infections and upper
airway complications (Cooper et al., 2001); however, the possi-
bility of immune dysfunction in CCD individuals remained unex-
plored. Here, we have addressed this question by assessing the
consequences of the loss of one allele of mouse Runx2. These
mice harbored substantially diminished numbers of pDCs in
the periphery compared to their WT littermates and had a similar,
albeit milder reduction in the expression of key integrins, IRF7,
and aberrant expression of CXCR4, compared to Runx2 cKO
mice. Interestingly, humans displaying gain-of-function mutation
in the CXCR4 gene, resulting in increase sensitivity of immune
cells to CXCL12, have a substantially reduced number of blood
pDCs and undetectable response to herpes simplex virus (Tas-
sone et al., 2010). Taken together, these observations lead us
to postulate that CCDpatientsmay have an impaired antiviral im-
mune response.
Plasmacytoid DCs are well known as early producers of IFN-a
(Cella et al., 1999; Macal et al., 2012; Siegal et al., 1999; Wang
et al., 2012), a process tightly controlled by IRF7 (Honda et al.,
2005). IFN-a expression by pDCs early after infection fulfills a
dual role, initiating a positive feedback loop to further increase
type I IFN production (Marie´ et al., 1998; Tailor et al., 2007) but
also negatively controlling peripheral pDC numbers through anintrinsic cell death pathway, thereby providing a mechanism to
prevent excessive production of type I IFN (Swiecki et al.,
2011). In keeping with this role as early producers of IFN-a,
mouse harboring reduced numbers of peripheral pDCs have
impaired immune responses to viral infection (Cervantes-Barra-
gan et al., 2007, 2012; Jung et al., 2008; Tassone et al., 2010).
Yet, the importance of pDCs to viral responses has been chal-
lenged in a study where pDCswere depleted usingmAb directed
against Bst2 (Hervas-Stubbs et al., 2014). In that study, although
pDCs were ablated from the spleen after mAb treatment, the
serum concentration of IFN-a remained comparable to mice
treated with the isotype control mAb. The role of pDCs is likely
to be context dependent as studies utilizing diphtheria toxin
(DT)-mediated depletion of pDCs expressing the DT receptor
from theClec4c gene have found that pDCs contribute to control
of systemic, but not local, Herpes simplex virus (Swiecki et al.,
2013) and murine cytomegalovirus infections (Swiecki et al.,
2010).
The role for pDCs in LCMV infection is similarly controversial,
as pDC depletion has been reported to have little impact on
acute LCMV (Armstrong) infection (Cervantes-Barragan et al.,
2012; Wang et al., 2012), but impaired T cell responses to
chronic LCMV (Docile) infection (Cervantes-Barragan et al.,
2012). To shed light on the causes of these discrepancies, we as-
sessed the response of Runx2 cKO mice to acute LCMV (WE)
infection and found that RUNX2 was essential for early IFN-a
expression. The early events associated with pDC deficiency
dictated the outcome of the adaptive response, as pDCs were
necessary for efficient CD8+ T responses and to fully control viral
burden. One possible explanation for the marked differences in
conclusions between these studies is that the preceding ap-
proaches depleted pDCs, thus removing an important early
replicative niche for LCMV, as well as the early wave of IFN-a
production (Cervantes-Barragan et al., 2012; Wang et al.,
2012), while in Runx2 cKO mice pDCs remain, albeit inappropri-
ately located, but are severely impaired in their ability to produce
IFN-a. Thus, the Runx2 cKO model facilitates higher viral titers,
while concurrently evoking lower IFN-a responses.
We also found that reducing the frequency of pDCs by 50% re-
sulted in a marked reduction in serum IFN-a concentration and
increased viral load. This suggests that relatively small changes
in factors, such as RUNX2 and IRF7, that alter the magnitude of
the pDC-dependent type I IFN production, and the positive feed-
back loop, at the early stage of the infection, are likely to have a
pronounced impact on the outcome of the adaptive immune
response.EXPERIMENTAL PROCEDURES
Animals
Rosa26CreERT2 mice (Seibler et al., 2003) were crossed to Runx2fl/fl mice
(Owens et al., 2014) allowing the tamoxifen-mediated inactivation of Runx2
in all cells. 5 mg tamoxifen (Sigma-Aldrich) in corn oil was given to mice by
oral gavage on consecutive days. Experiments involved 8- to 12-week-old
mice unless otherwise stated. To generate BM chimeras, C57Bl/6Ly5.1 mice
were lethally irradiated (23 0.55 Gy) and reconstituted with either Ly5.2+ WT
(CreERT2+ Runx2+/+) orCreERT2+ Runx2fl/fl BM for at least 8 weeks. All proce-
dures were approved by The Walter and Eliza Hall Institute Animal Ethics
Committee.Cell Reports 15, 866–878, April 26, 2016 875
Antibodies and Flow Cytometry
Flow cytometry was carried out as described in Supplemental Experimental
Procedures.
Monoclonal Antibody Generation
Rat monoclonal antibodies against mouse RUNX2 were generated as
described in Supplemental Experimental Procedures.
Cell Isolation
Organs were harvested, minced into fine pieces, and incubated for 30 min in
PBS + 0.5% BSA containing collagenase and DNase (Gibco). BM single-cell
suspensions were obtained by flushing the bones.
Dendritic Cell Culture
Isolated BM cells were cultured in mouse tonicity RPMI-1640 supplemented
with 10% heat inactivated fetal calf serum, 2 mM L-glutamine (Gibco),
50 mM 2-mercaptoethanol (Sigma) 100 U/ml penicillin/streptomycin (Gibco).
1.5 3 106 cells/ml were stimulated with Flt3L (100 ng/ml, PeproTech) for
7 days.
Adhesion Assay
96-well plates (Nunc polySorb) were coated overnight at 4C with 10 mg of Fc-
ICAM-1 (R&D Systems) or 10 mg Fibronectin Adhesion-promoting Peptide
(Sigma). BM cells were resuspended in adhesion buffer (20 mM Tris [pH 8],
150 mM NaCl, 1 mM CaCl2, 1 mM MgCl2, and 0.5% BSA) ± 5 mM EDTA,
EGTA and added to the coated well (1 3 106 cells/100 ml). Cells were left on
to adhere for 30 min. Non-adherent cells were removed by four washes with
the adhesion buffer. Adherent cells were detached in RPMI + 50 mM EDTA
at 4C under gentle agitation, washed in fluorescence-activated cell sorting
(FACS) buffer, and stained for B220 and Bst2. The percentage of adherent
cells was determined by comparison the number of adherent cells with the
cell input.
Lymphocytic Choriomeningitis Virus Infection
BM chimeric mice were infected with LCMV by i.v. injection of 3 3 103 PFU
of LCMV WE strain. Mice were sacrificed at day 8 post-infection, and
LCMV-specific CD8+ T cell responses were quantified with MHCI tetramers
(H-2Db) in complex with either LCMV gp33 (KAVYNFATM) or LCMV NP396
(FQPQNGQFI) (Baylor College of Medicine). For the restimulation, LCMV anti-
gen-specific peptide gp33 (100nM) was added to splenocytes in presence of
the GolgiPlug (BD Bioscience) for 4 hr. Granzyme B expression and IFN-g pro-
duction by CD8+ T cells was measured by flow cytometry. LCMV titers were
quantified by focus-forming assays using MC57 fibroblast cells as previously
described (Battegay et al., 1991).
RT-PCR
RNAs were isolated using RNeasy Plus Mini Kit, and cDNAs were synthesized
using iScript Reverse transcription supermix (Bio-Rad). Amplification was per-
formed with SYBR green master mix (Biolabs) on a Biorad CFX 384 using the
primers described in Supplemental Experimental Procedures.
Retroviral Transduction
The retroviral supernatants were produced using the pMIG (empty vector),
pMIG-Runx2 vectors as described in Chopin et al. (2013). 48-hr post-infection
cells were harvested and stained for flow cytometry analysis.
IFN-a ELISA
Quantitative levels of IFN-a were measured using the VeriKine Mouse IFN-a
ELISA kit (PBL Assay Science).
Chemotaxis Assay
BM cells were resuspended at a concentration of 107 cells/ml in RPMI-1640 +
10 mMHEPES and starved for 2 hr. Triplicate aliquots of 100 ml of cell suspen-
sion were plated in 6.5-mm Transwell inserts (5 mm pore size, Corning Costar).
The lower chamber was filled with medium containing different concentrations
of CXCL12 (PeproTech). After 3 hr, cells in the lower chamber were collected,
stainedwith antibodies against B220, Bst2, CD11c, and CD19, resuspended in876 Cell Reports 15, 866–878, April 26, 2016250 ml of PBS, and counted by flow cytometry at a standardized flow rate for
1min. Aliquots of input cells were processed and counted in the samemanner.
Percentage of migrated cells was expressed as the ratio of migrated cells
compared with the input cells.
AMD3100 Treatment and mAb Injection
AMD3100 treatment was performed as described in Beck et al. (2014). BM si-
nusoidal cells were labeled by i.v. injection of 1 mg of labeled rat anti-mouse
CD45.2 or B220 in 100 ml PBS. 2 min later, mice were sacrificed in a CO2
chamber.
ChIP
The RUNX2 ChIP-seq data from MC3T3 cells have been previously described
and deposited in GEO (GEO: GSE41955) (Meyer et al., 2014). pDCs were
generated from Flt3L cultures as described above and were sorted according
to the surface expression of CD11c and SiglecH and subjected to ChIP using a
polyclonal antibody recognizing PU.1 (T-20, Santa Cruz Biotechnology), as
described (Chopin et al., 2013). The ChIP-precipitated DNA was used for li-
brary preparation using the TruSeq DNA kit (Illumina) and Illumina deep
sequencing (2–3 3 107 single-end 50-bp reads). Sequences were aligned to
themouse genome (mm10) using Subread (Liao et al., 2013), with uniquemap-
ping turned on and ties split by Hamming distance.
Statistical Analyses
Significance of differences was assessed using unpaired Student’s t tests.
Statistical significance was set at p < 0.05.
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org/10.1016/j.celrep.2016.03.066.
AUTHOR CONTRIBUTIONS
Conceptualization, M.C.; Methodology, M.C., G.K.S., M.P., and G.T.B.; Inves-
tigation, S.P.P., A.T.L.L., and J.T.; Writing – Original Draft, M.C.; Writing – Re-
view & Editing, M.C. and S.L.N.; Resources, L.M.C. and J.E.V.; Supervision,
L.W. and S.L.N.
ACKNOWLEDGMENTS
We thank J. Leahy, E. Lanera, A. D’Amico, T. Kratina, D. Emslie, and the insti-
tute flow cytometry facility for technical assistance. This work was supported
by grants (1048278, 1023266, 1045549, 361646, 1065626, and 1016701) and
fellowships (to L.W., G.T.B., and S.L.N.) from the National Health and Medical
Research Council (NHMRC) of Australia. S.L.N. and G.T.B were supported by
an Australian Research Council Future Fellowship, J.E.V. was supported by an
Australia Fellowship, M.P. held a Viertel Fellowship, and L.W. was supported
by a Key Project Grant from the Natural Science Foundation of China
(31330027). This work wasmade possible through Victorian State Government
Operational Infrastructure Support and the NHMRC IRIIS.
Received: July 17, 2015
Revised: February 18, 2016
Accepted: March 16, 2016
Published: April 14, 2016
REFERENCES
Arsenio, J., Kakaradov, B., Metz, P.J., Kim, S.H., Yeo, G.W., and Chang, J.T.
(2014). Early specification of CD8+ T lymphocyte fates during adaptive immu-
nity revealed by single-cell gene-expression analyses. Nat. Immunol. 15,
365–372.
Battegay, M., Cooper, S., Althage, A., Ba¨nziger, J., Hengartner, H., and Zinker-
nagel, R.M. (1991). Quantification of lymphocytic choriomeningitis virus with
an immunological focus assay in 24- or 96-well plates. J. Virol. Methods 33,
191–198.
Beck, T.C., Gomes, A.C., Cyster, J.G., and Pereira, J.P. (2014). CXCR4 and a
cell-extrinsic mechanism control immature B lymphocyte egress from bone
marrow. J. Exp. Med. 211, 2567–2581.
Broxmeyer, H.E., Orschell, C.M., Clapp, D.W., Hangoc, G., Cooper, S., Plett,
P.A., Liles, W.C., Li, X., Graham-Evans, B., Campbell, T.B., et al. (2005). Rapid
mobilization of murine and human hematopoietic stem and progenitor cells
with AMD3100, a CXCR4 antagonist. J. Exp. Med. 201, 1307–1318.
Cella, M., Jarrossay, D., Facchetti, F., Alebardi, O., Nakajima, H., Lanzavec-
chia, A., and Colonna, M. (1999). Plasmacytoid monocytes migrate to inflamed
lymph nodes and produce large amounts of type I interferon. Nat. Med. 5,
919–923.
Cervantes-Barragan, L., Z€ust, R., Weber, F., Spiegel, M., Lang, K.S., Akira, S.,
Thiel, V., and Ludewig, B. (2007). Control of coronavirus infection through plas-
macytoid dendritic-cell-derived type I interferon. Blood 109, 1131–1137.
Cervantes-Barragan, L., Lewis, K.L., Firner, S., Thiel, V., Hugues, S., Reith, W.,
Ludewig, B., and Reizis, B. (2012). Plasmacytoid dendritic cells control T-cell
response to chronic viral infection. Proc. Natl. Acad. Sci. USA 109, 3012–3017.
Chopin, M., Seillet, C., Chevrier, S., Wu, L., Wang, H., Morse, H.C., 3rd, Belz,
G.T., and Nutt, S.L. (2013). Langerhans cells are generated by two distinct
PU.1-dependent transcriptional networks. J. Exp. Med. 210, 2967–2980.
Cisse, B., Caton, M.L., Lehner, M., Maeda, T., Scheu, S., Locksley, R., Holm-
berg, D., Zweier, C., den Hollander, N.S., Kant, S.G., et al. (2008). Transcription
factor E2-2 is an essential and specific regulator of plasmacytoid dendritic cell
development. Cell 135, 37–48.
Cooper, S.C., Flaitz, C.M., Johnston, D.A., Lee, B., and Hecht, J.T. (2001). A
natural history of cleidocranial dysplasia. Am. J. Med. Genet. 104, 1–6.
Crozat, K., Guiton, R., Guilliams, M., Henri, S., Baranek, T., Schwartz-Cornil, I.,
Malissen, B., and Dalod, M. (2010). Comparative genomics as a tool to reveal
functional equivalences between human and mouse dendritic cell subsets.
Immunol. Rev. 234, 177–198.
de la Rosa, G., Longo, N., Rodrı´guez-Ferna´ndez, J.L., Puig-Kroger, A., Pineda,
A., Corbı´, A.L., and Sa´nchez-Mateos, P. (2003). Migration of human blood den-
dritic cells across endothelial cell monolayers: adhesion molecules and che-
mokines involved in subset-specific transmigration. J. Leukoc. Biol. 73,
639–649.
Ghosh, H.S., Cisse, B., Bunin, A., Lewis, K.L., and Reizis, B. (2010). Contin-
uous expression of the transcription factor e2-2 maintains the cell fate of
mature plasmacytoid dendritic cells. Immunity 33, 905–916.
Gu, X., Hu, Z., Ebrahem, Q., Crabb, J.S., Mahfouz, R.Z., Radivoyevitch, T.,
Crabb, J.W., and Saunthararajah, Y. (2014). Runx1 regulation of Pu.1 core-
pressor/coactivator exchange identifies specific molecular targets for leuke-
mia differentiation therapy. J. Biol. Chem. 289, 14881–14895.
Hervas-Stubbs, S., Riezu-Boj, J.I., Manchen˜o, U., Rueda, P., Lopez, L.,
Alignani, D., Rodrı´guez-Garcı´a, E., Thieblemont, N., and Leclerc, C. (2014).
Conventional but not plasmacytoid dendritic cells foster the systemic virus-
induced type I IFN response needed for efficient CD8 T cell priming.
J. Immunol. 193, 1151–1161.
Honda, K., Yanai, H., Negishi, H., Asagiri, M., Sato, M., Mizutani, T., Shimada,
N., Ohba, Y., Takaoka, A., Yoshida, N., and Taniguchi, T. (2005). IRF-7 is the
master regulator of type-I interferon-dependent immune responses. Nature
434, 772–777.
Hu, G., and Chen, J. (2013). A genome-wide regulatory network identifies key
transcription factors for memory CD8+ T-cell development. Nat. Commun. 4,
2830.
Jung, A., Kato, H., Kumagai, Y., Kumar, H., Kawai, T., Takeuchi, O., and Akira,
S. (2008). Lymphocytoid choriomeningitis virus activates plasmacytoid den-
dritic cells and induces a cytotoxic T-cell response via MyD88. J. Virol. 82,
196–206.
Kamogawa-Schifter, Y., Ohkawa, J., Namiki, S., Arai, N., Arai, K., and Liu, Y.
(2005). Ly49Q defines 2 pDC subsets in mice. Blood 105, 2787–2792.Kohara, H., Omatsu, Y., Sugiyama, T., Noda, M., Fujii, N., and Nagasawa, T.
(2007). Development of plasmacytoid dendritic cells in bone marrow stromal
cell niches requires CXCL12-CXCR4 chemokine signaling. Blood 110, 4153–
4160.
Komori, T., Yagi, H., Nomura, S., Yamaguchi, A., Sasaki, K., Deguchi, K., Shi-
mizu, Y., Bronson, R.T., Gao, Y.H., Inada, M., et al. (1997). Targeted disruption
of Cbfa1 results in a complete lack of bone formation owing to maturational
arrest of osteoblasts. Cell 89, 755–764.
Krug, A., Uppaluri, R., Facchetti, F., Dorner, B.G., Sheehan, K.C., Schreiber,
R.D., Cella, M., and Colonna, M. (2002). IFN-producing cells respond to
CXCR3 ligands in the presence of CXCL12 and secrete inflammatory chemo-
kines upon activation. J. Immunol. 169, 6079–6083.
Liao, Y., Smyth, G.K., and Shi, W. (2013). The Subread aligner: fast, accurate
and scalable read mapping by seed-and-vote. Nucleic Acids Res. 41, e108.
Liles, W.C., Broxmeyer, H.E., Rodger, E., Wood, B., H€ubel, K., Cooper, S.,
Hangoc, G., Bridger, G.J., Henson, G.W., Calandra, G., and Dale, D.C.
(2003). Mobilization of hematopoietic progenitor cells in healthy volunteers
by AMD3100, a CXCR4 antagonist. Blood 102, 2728–2730.
Macal, M., Lewis, G.M., Kunz, S., Flavell, R., Harker, J.A., and Zu´n˜iga, E.I.
(2012). Plasmacytoid dendritic cells are productively infected and activated
through TLR-7 early after arenavirus infection. Cell Host Microbe 11, 617–630.
Manh, T.P., Alexandre, Y., Baranek, T., Crozat, K., and Dalod, M. (2013). Plas-
macytoid, conventional, and monocyte-derived dendritic cells undergo a pro-
found and convergent genetic reprogramming during their maturation. Eur. J.
Immunol. 43, 1706–1715.
Marie´, I., Durbin, J.E., and Levy, D.E. (1998). Differential viral induction of
distinct interferon-alpha genes by positive feedback through interferon regula-
tory factor-7. EMBO J. 17, 6660–6669.
Meyer, M.B., Benkusky, N.A., and Pike, J.W. (2014). The RUNX2 cistrome in
osteoblasts: characterization, down-regulation following differentiation, and
relationship to gene expression. J. Biol. Chem. 289, 16016–16031.
Miller, J.C., Brown, B.D., Shay, T., Gautier, E.L., Jojic, V., Cohain, A., Pandey,
G., Leboeuf, M., Elpek, K.G., Helft, J., et al.; Immunological Genome Con-
sortium (2012). Deciphering the transcriptional network of the dendritic cell
lineage. Nat. Immunol. 13, 888–899.
Mundlos, S., Otto, F., Mundlos, C., Mulliken, J.B., Aylsworth, A.S., Albright, S.,
Lindhout, D., Cole, W.G., Henn, W., Knoll, J.H., et al. (1997). Mutations
involving the transcription factor CBFA1 cause cleidocranial dysplasia. Cell
89, 773–779.
Otto, F., Thornell, A.P., Crompton, T., Denzel, A., Gilmour, K.C., Rosewell, I.R.,
Stamp, G.W., Beddington, R.S., Mundlos, S., Olsen, B.R., et al. (1997). Cbfa1,
a candidate gene for cleidocranial dysplasia syndrome, is essential for osteo-
blast differentiation and bone development. Cell 89, 765–771.
Owens, T.W., Rogers, R.L., Best, S.A., Ledger, A., Mooney, A.M., Ferguson,
A., Shore, P., Swarbrick, A., Ormandy, C.J., Simpson, P.T., et al. (2014).
Runx2 is a novel regulator of mammary epithelial cell fate in development
and breast cancer. Cancer Res. 74, 5277–5286.
Penna, G., Vulcano, M., Sozzani, S., and Adorini, L. (2002). Differential migra-
tion behavior and chemokine production by myeloid and plasmacytoid den-
dritic cells. Hum. Immunol. 63, 1164–1171.
Pereira, J.P., An, J., Xu, Y., Huang, Y., and Cyster, J.G. (2009). Cannabinoid
receptor 2 mediates the retention of immature B cells in bone marrow sinu-
soids. Nat. Immunol. 10, 403–411.
Petrovick, M.S., Hiebert, S.W., Friedman, A.D., Hetherington, C.J., Tenen,
D.G., and Zhang, D.E. (1998). Multiple functional domains of AML1: PU.1
and C/EBPalpha synergize with different regions of AML1. Mol. Cell. Biol.
18, 3915–3925.
Ro¨nnblom, L., Forsgren, A., and Alm, G.V. (1983). Characterization of inter-
ferons induced by bacteria and interferon-producing leukocytes in human pe-
ripheral blood. Infect. Immun. 40, 126–132.
Satpathy, A.T., Brisen˜o, C.G., Cai, X., Michael, D.G., Chou, C., Hsiung, S.,
Bhattacharya, D., Speck, N.A., and Egawa, T. (2014). Runx1 and Cbfb regulateCell Reports 15, 866–878, April 26, 2016 877
the development of Flt3+ dendritic cell progenitors and restrict myeloprolifer-
ative disorder. Blood 123, 2968–2977.
Sawai, C.M., Sisirak, V., Ghosh, H.S., Hou, E.Z., Ceribelli, M., Staudt, L.M., and
Reizis, B. (2013). Transcription factor Runx2 controls the development and
migration of plasmacytoid dendritic cells. J. Exp. Med. 210, 2151–2159.
Seibler, J., Zevnik, B., K€uter-Luks, B., Andreas, S., Kern, H., Hennek, T., Rode,
A., Heimann, C., Faust, N., Kauselmann, G., et al. (2003). Rapid generation of
inducible mouse mutants. Nucleic Acids Res. 31, e12.
Siegal, F.P., Kadowaki, N., Shodell, M., Fitzgerald-Bocarsly, P.A., Shah, K.,
Ho, S., Antonenko, S., and Liu, Y.J. (1999). The nature of the principal type 1
interferon-producing cells in human blood. Science 284, 1835–1837.
Swiecki, M., Gilfillan, S., Vermi, W., Wang, Y., and Colonna, M. (2010). Plasma-
cytoid dendritic cell ablation impacts early interferon responses and antiviral
NK and CD8(+) T cell accrual. Immunity 33, 955–966.
Swiecki, M.,Wang, Y., Vermi,W., Gilfillan, S., Schreiber, R.D., andColonna,M.
(2011). Type I interferon negatively controls plasmacytoid dendritic cell
numbers in vivo. J. Exp. Med. 208, 2367–2374.
Swiecki, M., Wang, Y., Gilfillan, S., and Colonna, M. (2013). Plasmacytoid den-
dritic cells contribute to systemic but not local antiviral responses to HSV in-
fections. PLoS Pathog. 9, e1003728.878 Cell Reports 15, 866–878, April 26, 2016Tailor, P., Tamura, T., Kong, H.J., Kubota, T., Kubota, M., Borghi, P., Gabri-
ele, L., and Ozato, K. (2007). The feedback phase of type I interferon induc-
tion in dendritic cells requires interferon regulatory factor 8. Immunity 27,
228–239.
Tassone, L., Moratto, D., Vermi, W., De Francesco, M., Notarangelo, L.D.,
Porta, F., Lougaris, V., Facchetti, F., Plebani, A., and Badolato, R. (2010).
Defect of plasmacytoid dendritic cells in warts, hypogammaglobulinemia,
infections, myelokathexis (WHIM) syndrome patients. Blood 116, 4870–
4873.
Vanbervliet, B., Bendriss-Vermare, N., Massacrier, C., Homey, B., de Bouteil-
ler, O., Brie`re, F., Trinchieri, G., and Caux, C. (2003). The inducible CXCR3 li-
gands control plasmacytoid dendritic cell responsiveness to the constitutive
chemokine stromal cell-derived factor 1 (SDF-1)/CXCL12. J. Exp. Med. 198,
823–830.
Wang, Y., Swiecki, M., Cella, M., Alber, G., Schreiber, R.D., Gilfillan, S., and
Colonna, M. (2012). Timing and magnitude of type I interferon responses by
distinct sensors impact CD8 T cell exhaustion and chronic viral infection.
Cell Host Microbe 11, 631–642.
Zlotnik, A., and Yoshie, O. (2000). Chemokines: a new classification system
and their role in immunity. Immunity 12, 121–127.
